Oya K, Nakamura Y, Fujisawa Y, Nomura T, et al. Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin'. Br J Dermatol 2022 Mar 9. doi: 10.1111/bjd.21230.
PMID: 35261023